用于药物发现的多组份中药配方:现状和未来展望

Cheng Zhang, Guoming Chen, Guoyi Tang, Xiaoyu Xu, Z. Feng, Yuanjun Lu, Y. Chan, Junyu Wu, Yuanyuan Chen, Lin Xu, Qing-li Ren, Hongchao Yuan, Dong Yang, Zhe-Sheng Chen, Ning Wang, Yibin Feng
{"title":"用于药物发现的多组份中药配方:现状和未来展望","authors":"Cheng Zhang, Guoming Chen, Guoyi Tang, Xiaoyu Xu, Z. Feng, Yuanjun Lu, Y. Chan, Junyu Wu, Yuanyuan Chen, Lin Xu, Qing-li Ren, Hongchao Yuan, Dong Yang, Zhe-Sheng Chen, Ning Wang, Yibin Feng","doi":"10.15212/amm-2022-0049","DOIUrl":null,"url":null,"abstract":"For hundreds of years, the drug discovery and development industry has aimed at identifying single components with a clear mechanism of action as desirable candidates for potential drugs. However, this conventional strategy of drug discovery and development has faced challenges including a low success rate and high development costs. Herein, we critically review state-of-the-art drug discovery and development based on multi-component Chinese medicine formulas. We review the policies and application status of new drugs based on multi-component Chinese medicines in the US, China, and the European Union. Moreover, we illustrate several excellent cases of ongoing applications. Biomedical technologies that may facilitate drug discovery and development based on multi-component Chinese medicine formulas are discussed, including network pharmacology, integrative omics, CRISPR gene editing, and chemometrics. Finally, we discuss potential problems and solutions in pre-clinical and clinical research in drug discovery and development based on multi-component Chinese medicine formulas. We hope that this review will promote discussion of the roles of multi-component Chinese medicine formulas in the discovery and development of new drugs for the treatment of human diseases.","PeriodicalId":72055,"journal":{"name":"Acta materia medica","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Multi-component Chinese medicine formulas for drug discovery: State of the art and future perspectives\",\"authors\":\"Cheng Zhang, Guoming Chen, Guoyi Tang, Xiaoyu Xu, Z. Feng, Yuanjun Lu, Y. Chan, Junyu Wu, Yuanyuan Chen, Lin Xu, Qing-li Ren, Hongchao Yuan, Dong Yang, Zhe-Sheng Chen, Ning Wang, Yibin Feng\",\"doi\":\"10.15212/amm-2022-0049\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"For hundreds of years, the drug discovery and development industry has aimed at identifying single components with a clear mechanism of action as desirable candidates for potential drugs. However, this conventional strategy of drug discovery and development has faced challenges including a low success rate and high development costs. Herein, we critically review state-of-the-art drug discovery and development based on multi-component Chinese medicine formulas. We review the policies and application status of new drugs based on multi-component Chinese medicines in the US, China, and the European Union. Moreover, we illustrate several excellent cases of ongoing applications. Biomedical technologies that may facilitate drug discovery and development based on multi-component Chinese medicine formulas are discussed, including network pharmacology, integrative omics, CRISPR gene editing, and chemometrics. Finally, we discuss potential problems and solutions in pre-clinical and clinical research in drug discovery and development based on multi-component Chinese medicine formulas. We hope that this review will promote discussion of the roles of multi-component Chinese medicine formulas in the discovery and development of new drugs for the treatment of human diseases.\",\"PeriodicalId\":72055,\"journal\":{\"name\":\"Acta materia medica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta materia medica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15212/amm-2022-0049\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta materia medica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15212/amm-2022-0049","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

摘要

数百年来,药物发现和开发行业一直致力于识别具有明确作用机制的单一成分,作为潜在药物的理想候选物。然而,这种传统的药物发现和开发策略面临着包括低成功率和高开发成本在内的挑战。在此,我们批判性地回顾了基于多组分中药配方的最新药物发现和开发。本文综述了美国、中国和欧盟基于多组分中药的新药的政策和应用现状。此外,我们还举例说明了几个正在进行的应用程序的优秀案例。讨论了可能促进基于多组分中药方剂的药物发现和开发的生物医学技术,包括网络药理学、整合组学、CRISPR基因编辑和化学计量学。最后,我们讨论了基于多组份中药方剂的药物发现和开发在临床前和临床研究中可能存在的问题和解决方案。我们希望这篇综述能促进对多组份中药方剂在发现和开发治疗人类疾病的新药中的作用的讨论。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Multi-component Chinese medicine formulas for drug discovery: State of the art and future perspectives
For hundreds of years, the drug discovery and development industry has aimed at identifying single components with a clear mechanism of action as desirable candidates for potential drugs. However, this conventional strategy of drug discovery and development has faced challenges including a low success rate and high development costs. Herein, we critically review state-of-the-art drug discovery and development based on multi-component Chinese medicine formulas. We review the policies and application status of new drugs based on multi-component Chinese medicines in the US, China, and the European Union. Moreover, we illustrate several excellent cases of ongoing applications. Biomedical technologies that may facilitate drug discovery and development based on multi-component Chinese medicine formulas are discussed, including network pharmacology, integrative omics, CRISPR gene editing, and chemometrics. Finally, we discuss potential problems and solutions in pre-clinical and clinical research in drug discovery and development based on multi-component Chinese medicine formulas. We hope that this review will promote discussion of the roles of multi-component Chinese medicine formulas in the discovery and development of new drugs for the treatment of human diseases.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives. Application of PROTACs in Target Identification and Target Validation. PROTACs Targeting Epigenetic Proteins. Exploitation of platelets for antitumor drug delivery and modulation of the tumor immune microenvironment Emerging role of HJURP as a therapeutic target in cancers
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1